Extent of uncontrolled disease and associated medical costs in severe asthma - A PHARMO study

Current Medical Research and Opinion

Volumn 24, Issue 4, 2008, Pages 975-983

  Breekveldt Postma, Nancy S ^a   Erkens, Joëlle A ^a   Aalbers, René ^b   Van De Ven, Marjo J T ^c   Lammers, Jan Willem J ^d   Herings, Ron M C ^a,e  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Control; Costs; Drug utilization; Hospital admission; Prevalence; Severe asthma

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; NEDOCROMIL; SHORT ACTING DRUG; XANTHINE;

ADOLESCENT; ADULT; ASTHMA; CONFERENCE PAPER; CORTICOSTEROID THERAPY; COST OF ILLNESS; DISEASE CONTROL; DISEASE SEVERITY; DRUG USE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; REIMBURSEMENT; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ASTHMA; CASE-CONTROL STUDIES; CHILD; DRUG UTILIZATION; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 42549154928     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X280518     Document Type: Conference Paper

References (19)

1. Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma. Developed for the global initiative for asthma: Medical Research Institute of New Zealand, Wellington, New Zealand and University of Southampton, Southampton, United Kingdom; 2003
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78
3. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23:723-9
4. Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003;111:1212-8
5. Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002;19:61-7
6. Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322-6
7. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636-42
8. Global strategy for asthma management and prevention - revised 2006. Global initiative for asthma, 2006. http://www. ginasthma.org/Guidelineitem.asp? ?l1=2&12=1&intId=60.) [accessed December 20, 2006]
9. Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32-9
10. Sullivan SD. Asthma in the United States: recent trends and current status. J Manag Care Pharm 2003;9(Suppl 5):3-7
11. Stern L, Berman J, Lumry W, et al. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data. Ann Allergy Asthma Immunol 2006;97:402-8
12. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-44
13. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13
14. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. Asthma exacerbations during first therapy with long acting beta 2-agonists. Pharm World Sci 1999;21:116-9
15. Van Ganse E, Laforest L, Pietri G, et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J 2002;20:260-7
16. Hoskins G, McCowan C, Neville RG, et al. Risk factors and costs associated with an asthma attack. Thorax 2000;55:19-24
17. Spector S. Noncompliance with asthma therapy - are there solutions? J Asthma 2000;37:381-8
18. Kaiser HB. Compliance and noncompliance in asthma. Allergy Asthma Proc 2007;28:514-6
19. Sullivan SD, Rasouliyan L, Russo PA, et al. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007;62:126-33